|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue, net | |||||
| Cost of product revenue (excluding $X and $X in intangible asset amortization for the years ended XXX XX, 20XX, and 20XX, respectively, shown separately below) | |||||
| Intangible asset amortization | |||||
| Impairment of intangible assets | |||||
| Operating expenses: | |||||
| Cost of revenue | |||||
| Research and development | |||||
| Selling, general and administrative | |||||
| Acquired in-process research and development | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other income (expense): | |||||
| Gain on sale of PRV | |||||
| Interest expense | |||||
| Fair value adjustment related to warrant and CVR liability | |||||
| Fair value adjustment related to investments | |||||
| Interest and other income, net | |||||
| Total other income (expense) | |||||
| Income (loss) before income taxes | |||||
| Income tax expense | |||||
| Net income (loss) | |||||
| Net loss attributable to common stockholders | |||||
| Net income (loss) per share of common stock: | |||||
| Basic (in dollars per share) | |||||
| Diluted (in dollars per share) | |||||
| Weighted-average shares of common stock outstanding: | |||||
| Basic (in shares) | |||||
| Diluted (in shares) | |||||
Loading...